Business Segments Arrowhead Pharmaceuticals, Inc.
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.69 USD | -6.75% |
|
-2.83% | +9.49% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Nanotechnology | 138M | 243M | 241M | - | 829M | |||||
Total Assets | 710M | 692M | 766M | - | 1.39B | |||||
Interest Expense | - | - | -18.33M | - | -89.36M | |||||
Income Tax Expense | 2K | 3.78M | 2.78M | - | 21.42M | |||||
CAPEX | -23.57M | -52.78M | -177M | - | -22.67M | |||||
EBT | -141M | -173M | -206M | - | 51.53M | |||||
D&A | 8.27M | 10.42M | 12.49M | - | 23.93M | |||||
Operating Income | -149M | -179M | -205M | - | 98.35M | |||||
Net Income | -141M | -176M | -205M | - | -1.63M |
Geographical Revenue Distribution History
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 138M | 243M | 241M | - | 829M | |||||
Total Assets | 710M | 692M | 766M | - | 1.39B | |||||
Interest Expense | - | - | -18.33M | - | -89.36M | |||||
Income Tax Expense | 2K | 3.78M | 2.78M | - | 21.42M | |||||
D&A | 8.27M | 10.42M | 12.49M | - | 23.93M | |||||
CAPEX | -23.57M | -52.78M | -177M | - | -22.67M | |||||
Net Income | -141M | -176M | -205M | - | -1.63M | |||||
EBT | -141M | -173M | -206M | - | 51.53M | |||||
Operating Income | -149M | -179M | -205M | - | 98.35M |
- Stock Market
- Equities
- ARWR Stock
- Financials Arrowhead Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition